Ress Life Investments A/S publishes Half-Year Report 1 January 2026 – 30 June 2026

Ress Life Investments reported H1 2026 net profit of $6.66 million, equivalent to a 3.2% return on equity and EPS of $57.34, with NAV rising by $83.69 per share to $2,722 at 30 June. Equity was $225.45 million, while the company’s $129 million earnout asset from the sale of most policies remains subject to a dispute with the purchaser. Management said H1 profit was on target and reiterated target USD net returns of 7.0% for 2026 and 10% from 2027 onward.

Analysis

RES is transitioning from a direct life-settlement underwriting vehicle toward a concentrated, long-duration receivable whose value depends on a counterparty’s future collections. The reported NAV improvement is therefore less informative than the quality, enforceability and liquidity of the earnout: at roughly 57% of equity, even a modest impairment or payment-delay assumption change could overwhelm a year of targeted returns. The purchaser dispute should command a materially wider discount to stated NAV until the claim hierarchy, collateral and payment timetable are independently disclosed.

Near term, the main catalyst is not operating performance but resolution milestones in the dispute and any audit evidence supporting the earnout valuation. Over the next 1-3 months, an adverse legal update, revised fair-value methodology, or delayed cash receipt could trigger NAV-mark concerns; conversely, a binding settlement with collateralized scheduled payments would reduce the conglomerate/legal discount. The 6-18 month upside case requires realized earnout cash flows to validate management’s yield assumptions, while the downside includes mortality-model revisions, discount-rate normalization and buyer credit deterioration occurring simultaneously.

Consensus may treat the target return as evidence that the portfolio can compound at double digits, but the economic exposure is now materially more binary than a diversified policy book. A high stated asset value without observable secondary-market pricing should be valued as a disputed structured credit instrument, not at par with liquid NAV. This is a verification trade, not an earnings-momentum trade.

Key Decisions for Investors

• Do not initiate a directional RES long solely on the half-year result; wait for disclosure of earnout collateral, legal jurisdiction, contractual payment waterfall and post-period cash collections.
• Set an event-driven long alert for RES if a settlement converts the earnout into secured, dated cash flows and the shares trade at a material discount to independently supportable NAV; target a 3-6 month rerating, with thesis invalidated by any earnout impairment or missed payment.
• For existing exposure, cap position sizing as a special-situations credit/legal risk rather than an alternative-asset manager holding; reassess immediately if the earnout fair value is reduced by more than 10%, which would have an outsized effect on equity value.
• Monitor the purchaser's credit quality and any litigation filings over the next quarter. Deteriorating credit spreads, covenant stress or lack of disclosed collateral would argue for reducing exposure regardless of reported portfolio yield.